Dr Chilton will have responsibility for the scientific services provided to the company’s customers from three locations in the US and one in the UK. For the past two years, Dr Chilton was in charge of early development programs at Atherogenics of Alpharetta, Georgia.
As part of his compensation package, the company has agreed to grant Dr Chilton incentive options to purchase 30,000 common shares under its 2008 employee incentive stock option plan at the per-share market price at the close of business on the last trading day prior to the date Dr Chilton commences employment with the company. The option grants are contingent upon Dr Chilton commencing employment with the company.